<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04971772</url>
  </required_header>
  <id_info>
    <org_study_id>FCRE-210621</org_study_id>
    <nct_id>NCT04971772</nct_id>
  </id_info>
  <brief_title>SIGNATURE Study : DCB (Legflow) vs POBA in Fempop Arteries</brief_title>
  <acronym>SIGNATURE</acronym>
  <official_title>SIGNATURE Study: Post-market, Randomized Controlled, Multicenter, Prospective Trial Investigating the Paclitaxel-Coated Balloon (Legflow DCB) Treatment Versus Uncoated Balloon Angioplasty Treatment for Femoro-popliteal Lesions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Giovanni Torsello</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FCRE (Foundation for Cardiovascular Research and Education)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to demonstrate the superiority in safety and efficacy of the Legflow&#xD;
      DCB vs standard uncoated POBA in a randomized controlled (RCT) for treatment of patients with&#xD;
      symptomatic peripheral artery disease (PAD) due to stenosis, restenosis or occlusion of the&#xD;
      femoral and/or popliteal arteries.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2022</start_date>
  <completion_date type="Anticipated">September 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Efficacy Endpoint:</measure>
    <time_frame>12 months post-procedure</time_frame>
    <description>freedom from clinically-driven target lesion revascularization (CD-TLR) at 12 months, defined as any reintervention at the target lesion due to symptoms OR drop of ankle brachial index (ABI) &gt;20% or ABI &gt;0.15 compared to the post-procedural ABI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety Endpoint:</measure>
    <time_frame>12 months post-procedure</time_frame>
    <description>Composite of: (1) Freedom from device- and procedure-related death through 30-days post-index procedure; (2) Freedom from major target limb amputation (above-the-ankle (ATA)) through 12 months post-procedure and (3) clinically-driven target vessel revascularization (CD-TVR) through 12 months post-index procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute device success</measure>
    <time_frame>during index procedure</time_frame>
    <description>defined as successful delivery, balloon inflation, deflation and retrieval of the intact study device without burst below rated burst pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute procedural success</measure>
    <time_frame>during index procedure</time_frame>
    <description>Acute procedural success is defined as restoration of the target lesion with ≤30% residual stenosis in the final angiogram.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary safety endpoint at discharge up to 30 days post-index procedure</measure>
    <time_frame>30 days post-operative</time_frame>
    <description>defined as freedom from all-cause death, major target limb amputation and CD-TVR through 30 days post index procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained clinical improvement at 6-, 12- and 24- months post-index procedure</measure>
    <time_frame>24-months post-operative</time_frame>
    <description>defined as freedom from major target limb amputation, TVR, worsening target limb Rutherford Class (compared to baseline) and decrease in target limb ankle brachial index (ABI) or toe brachial index (TBI) ≥ 0.15 (compared to baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Events (MAEs) at 6-, 12- and 24-months post-index procedure</measure>
    <time_frame>24-months post-operative</time_frame>
    <description>defined as composite of all-cause death, CD-TVR and major target limb amputation, or thrombosis at the target lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary Patency at 6-, 12- and 24-months</measure>
    <time_frame>24-months post-operative</time_frame>
    <description>defined as a composite of freedom from clinically-driven target lesion revascularization (CD-TLR) and binary restenosis (restenosis defined as duplex ultrasound (DUS) peak systolic velocity ratio (PSVR) ≥2.4 or ≥50% stenosis) through 24-months post-index procedure. (For 12-months: assessed by independent Core Lab)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization at 6-, 12- and 24-months post-index procedure</measure>
    <time_frame>24-months post-operative</time_frame>
    <description>defined as a reintervention to maintain or restore the patency in the target lesion. TLR is clinically-driven (CD) when the TLR was needed due to symptoms or drop of ankle brachial index (ABI) of ≥20% or &gt;0.15 when compared to post-procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization at 6-, 12- and 24-months post-index procedure</measure>
    <time_frame>24-months post-operative</time_frame>
    <description>defined as a reintervention to maintain or restore the patency in the target vessel. TVR is clinically-driven (CD) when the TVR was needed due to symptoms or drop of ankle brachial index (ABI) of ≥20% or &gt;0.15 when compared to post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binary restenosis at 6-, 12- and 24-months</measure>
    <time_frame>24-months post-operative</time_frame>
    <description>defined as a restenosis confirmed by DUS PSVR ≥2.4 or ≥50% stenosis (For 12-month: assessed by Independent Core-Lab)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Target Limb Amputation at 6-, 12- and 24-months</measure>
    <time_frame>24-months post-operative</time_frame>
    <description>defined as an amputation above the ankle (ATA) in the target limb</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombosis at the target lesion at 6-, 12- and 24-months</measure>
    <time_frame>24-months post-operative</time_frame>
    <description>Thrombosis at the target lesion at 6-, 12- and 24-months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death at 6-, 12- and 24-months</measure>
    <time_frame>24-months post-operative</time_frame>
    <description>All-cause death at 6-, 12- and 24-months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in target limb Rutherford Classification from baseline to 6-, 12- and 24-months</measure>
    <time_frame>24-months post-operative</time_frame>
    <description>Change in Target Limb Rutherford Classification from baseline to 6-, 12- and 24-months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Target Limb Resting ABI or TBI from baseline to 6-, 12- and 24-months</measure>
    <time_frame>24-months post-operative</time_frame>
    <description>Change in Target Limb Resting ABI or TBI from baseline to 6-, 12- and 24-months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of life quality according to the Walking Impairment Questionnaire (WIQ) and the EQ-5D Questionnaire to baseline at follow-up at 6-, 12- and 24-month.</measure>
    <time_frame>24-months post-operative</time_frame>
    <description>Improvement of life quality according to the Walking Impairment Questionnaire (WIQ) and the EQ-5D Questionnaire to baseline at follow-up at 6-, 12- and 24-month.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <condition>Superficial Femoral Artery Stenosis</condition>
  <condition>Angiopathy, Peripheral</condition>
  <arm_group>
    <arm_group_label>DCB (Legflow .035&quot;) group</arm_group_label>
    <description>treatment with Drug Coated Balloon angioplasty with the Legflow .035&quot; Paclitaxel Balloon Dilatation catheter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>POBA group</arm_group_label>
    <description>treatment with standard POBA (uncoated) angiplasty (type and brand at the physician's discretion)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with peripheral arterial disease in the SFA, eligible for treatment with the&#xD;
        paclitaxel coated Legflow dilatation balloon catheter&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Patient is ≥18 years&#xD;
&#xD;
          -  Patient has Rutherford Classification 2,3 or4.&#xD;
&#xD;
          -  Patient has provided written informed consent and is willing to comply with study&#xD;
             follow-up requirements.&#xD;
&#xD;
          -  De novo stenotic or occlusive lesion(s) or non-stented restenotic or occlusive&#xD;
             lesion(s) occurring &gt;90 days after prior plain old balloon (POBA) angioplasty or &gt;180&#xD;
             days after prior DCB treatment.&#xD;
&#xD;
          -  Target lesion is located between the ostium of the SFA and the end of the P1 segment&#xD;
             of the popliteal artery&#xD;
&#xD;
          -  Target vessel diameter ≥ 4 mm and ≤ 7 mm&#xD;
&#xD;
          -  Target lesion must be stenotic or occlusive lesion ≤ 150mm in length (one long lesion&#xD;
             or tandem lesions) by investigator's visual estimate. [Note: tandem lesions must have&#xD;
             a total length of ≤ 150 mm by visual estimate and be separated by ≤ 30 mm.]&#xD;
&#xD;
          -  Target lesion must have angiographic evidence of ≥ 70 % stenosis by investigator's&#xD;
             visual estimation&#xD;
&#xD;
          -  Successful, uncomplicated crossing of the target lesion occurs when the tip of the&#xD;
             guidewire is distal to the target lesion without the occurrence of flow-limiting&#xD;
             dissection of perforation and is judged by visual inspection to be within the true&#xD;
             lumen. Subintimal dissection techniques may be used if re-entry occurs above-the-knee&#xD;
             (ATK) and without the use of re-entry devices.&#xD;
&#xD;
          -  Target lesion is located at least 30mm from any stent if target vessel was previously&#xD;
             stented.&#xD;
&#xD;
          -  A patent inflow artery free from significant stenosis ((≥50% stenosis) as confirmed by&#xD;
             angiography.&#xD;
&#xD;
          -  At least one patent native outflow artery to the ankle or foot, free from significant&#xD;
             stenosis (≥ 50 % stenosis) as confirmed by angiography.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Acute Limb Ischemia&#xD;
&#xD;
          -  Patient underwent an intervention involving the target vessel within the previous 90&#xD;
             days.&#xD;
&#xD;
          -  Patient underwent any lower extremity percutaneous treatment in the ipsilateral limb&#xD;
             using a paclitaxel-eluting stent or DCB within the previous 90 days.&#xD;
&#xD;
          -  Patient underwent a percutaneous transluminal angioplasty (PTA) of the target lesion&#xD;
             using a DCB within the previous 180 days.&#xD;
&#xD;
          -  Pregnant women or women who are intending to become pregnant.&#xD;
&#xD;
          -  Patient has a life expectancy of less than 1 year&#xD;
&#xD;
          -  Patient has a known allergy to contrast medium that cannot be adequately&#xD;
             pre-medicated.&#xD;
&#xD;
          -  Patient is allergic to all anti-platelet treatments&#xD;
&#xD;
          -  Patient is receiving immunosuppressant therapy&#xD;
&#xD;
          -  Patient has platelet count &lt;100.000/mm3 or &gt;700.000/mm&#xD;
&#xD;
          -  Patient has history of gastrointestinal hemorrhage requiring a transfusion within 3&#xD;
             months prior to the study procedure&#xD;
&#xD;
          -  Patient is diagnosed with coagulopathy that precludes treatment with systemic&#xD;
             anticoagulation and/or dual antiplatelet therapy (DAPT)&#xD;
&#xD;
          -  Patient has history of stroke within past 90 days&#xD;
&#xD;
          -  Patient has history of myocardial infarction within the past 30 days.&#xD;
&#xD;
          -  Patient is participating in an investigational drug or medical device study that has&#xD;
             not completed primary endpoint(s) evaluation or that clinically interferes with the&#xD;
             endpoints from this study.&#xD;
&#xD;
          -  Patient has had any major (e.g. cardiac, peripheral, abdominal) surgical procedure or&#xD;
             intervention unrelated to this study within 30 days prior to the index procedure or&#xD;
             has planned major surgical procedure or intervention within 30 days of the index&#xD;
             procedure&#xD;
&#xD;
          -  An intervention in the contralateral limb, planned within 30 days post-index procedure&#xD;
&#xD;
          -  Patient had previous bypass surgery of the target lesion&#xD;
&#xD;
          -  Patient had previous treatment of the target vessel with thrombolysis or surgery&#xD;
&#xD;
          -  Patient is unwilling or unable to comply with procedures specified in the protocol or&#xD;
             has difficulty or inability to return for follow-up visits as specified by the&#xD;
             protocol&#xD;
&#xD;
          -  Target lesion involves an aneurysm or is adjacent to an aneurysm (within 5 mm)&#xD;
&#xD;
          -  Target Lesion requires treatment with alternative therapy such as stenting, laser,&#xD;
             atherectomy, cryoplasty, brachytherapy or re-entry devices&#xD;
&#xD;
          -  Significant target vessel tortuosity or other parameters prohibiting access to the&#xD;
             target lesion&#xD;
&#xD;
          -  Presence of thrombus in the target vessel&#xD;
&#xD;
          -  Iliac inflow disease requiring treatment, unless the iliac artery disease is&#xD;
             successfully treated first during the index procedure. Success is defined as ≤ 30 %&#xD;
             residual diameter stenosis without death or major complications.&#xD;
&#xD;
          -  Presence of an aortic, iliac or femoral artificial graft.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Annelena Held-Wehmöller, Dr.</last_name>
    <phone>+4915785128140</phone>
    <email>annelena.held@fcre.eu</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 20, 2021</study_first_submitted>
  <study_first_submitted_qc>July 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>FCRE (Foundation for Cardiovascular Research and Education)</investigator_affiliation>
    <investigator_full_name>Prof. Giovanni Torsello</investigator_full_name>
    <investigator_title>CEO FCRE</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

